Related Experiment Video
Updated: Aug 22, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Dexamethasone-eluting stent: an anti-inflammatory approach to inhibit coronary restenosis
Xiaoshun Liu1, Ivan De Scheerder, Walter Desmet
1Cardiac Catheterization Laboratory, University Hospital Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium. Xiaoshun.liu@med.kuleuven.ac.be
Insights
Dexamethasone-eluting stents may reduce restenosis after percutaneous coronary interventions by targeting inflammation. Ongoing trials will confirm the long-term efficacy of this approach in preventing artery narrowing.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Pharmacology
Background:
- Restenosis following percutaneous coronary interventions (PCI) remains a clinical challenge.
- Inflammation is a key driver of neointimal hyperplasia and restenosis post-PCI.
- Dexamethasone, a potent anti-inflammatory glucocorticoid, has shown potential in preventing restenosis.
Purpose of the Study:
- To review the role of inflammation in restenosis pathogenesis.
- To evaluate the efficacy of dexamethasone in preventing restenosis after PCI.
- To discuss the development and potential of dexamethasone-eluting stents.
Main Methods:
- Review of preclinical and clinical studies on inflammation in restenosis.
- Analysis of data from early trials of systemic and local dexamethasone delivery.
- Examination of findings from dexamethasone-eluting stent studies.
Main Results:
- Inflammation significantly contributes to the development of restenosis.
- Early dexamethasone interventions showed limited success.
- Preclinical studies and a pilot trial suggest dexamethasone-eluting stents are safe and reduce inflammation, with a potential benefit for restenosis.
Conclusions:
- Inflammation is a critical factor in restenosis after PCI.
- Dexamethasone-eluting stents represent a promising strategy for local drug delivery to combat restenosis.
- Larger randomized trials are necessary to validate the long-term efficacy of dexamethasone-eluting stents.
Abstract:
The long-term efficacy of percutaneous coronary interventions is still hampered by restenosis. Restenosis is the result of a complex pathophysiological process, which is thought to be caused by an exaggerated healing response induced by the vascular injury caused by the percutaneous coronary interventions and the implantation of a foreign body (the stent). There is increasing evidence that inflammation plays an important role in the initiation and development of neointimal hyperplasia and subsequent restenosis. Dexamethasone (Decadron, Merck Sharpe and Dohme Ltd) is a glucocorticoid with well-known potent anti-inflammatory and antiproliferative properties. Early studies using either systemic or local delivery of dexamethasone have shown limited beneficial effects on restenosis. The dexamethasone-eluting stent (Dexamet, Abbott Vascular Devices Ltd) is one of the first generation of drug-eluting stents for local drug delivery to prevent restenosis. Preclinical studies demonstrated that implantation of dexamethasone-loaded coronary stents was safe and had a beneficial effect on stent implantation-related inflammation. A pilot trial suggested a beneficial effect on restenosis. Large randomized trials are underway to confirm these findings. This article reviews the potential role of inflammation in the pathogenesis of restenosis and the efficacy of dexamethasone in the prevention of restenosis.
